Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (21-30 of 936) with videos related to

Pageof 94
Sort By:
Neuro-Oncology|June 25, 2014
The vanishing role of whole brain radiotherapy for primary central nervous system lymphomaMichael Weller
Expert Opinion on Investigational Drugs|March 15, 2012
Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?Katharina Seystahl, Michael Weller
Cancer Letters|January 29, 2011
Targeting apoptosis pathways in glioblastomaGünter Eisele, Michael Weller
Current Opinion in Neurology|September 23, 2009
Classification and management of anaplastic gliomasWolfgang Wick, Michael Weller
Current Opinion in Neurology|September 23, 2009
Approval of new drugs for glioblastomaMichael Weller, Roger Stupp
Nature Reviews. Neurology|March 3, 2021
Pathway-based stratification of glioblastomaTobias Weiss, Michael Weller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experienceWolfgang Wick, Michael Weller
Neuro-Oncology|May 16, 2014
Questions regarding the optimal use of bevacizumab in glioblastoma: a moving targetRoger Stupp, Michael Weller
Brain : a Journal of Neurology|November 25, 2015
New insights into acquired temozolomide resistance in glioblastoma?Caroline Happold, Michael Weller
Cancer|September 14, 2016
Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009Dorothee Gramatzki, Michael Weller
Pageof 94

Showing results (21-30 of 936) with videos related to

Sort By:
Pageof 94
Neuro-Oncology|June 25, 2014
The vanishing role of whole brain radiotherapy for primary central nervous system lymphomaMichael Weller
Expert Opinion on Investigational Drugs|March 15, 2012
Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?Katharina Seystahl, Michael Weller
Cancer Letters|January 29, 2011
Targeting apoptosis pathways in glioblastomaGünter Eisele, Michael Weller
Current Opinion in Neurology|September 23, 2009
Classification and management of anaplastic gliomasWolfgang Wick, Michael Weller
Current Opinion in Neurology|September 23, 2009
Approval of new drugs for glioblastomaMichael Weller, Roger Stupp
Nature Reviews. Neurology|March 3, 2021
Pathway-based stratification of glioblastomaTobias Weiss, Michael Weller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experienceWolfgang Wick, Michael Weller
Neuro-Oncology|May 16, 2014
Questions regarding the optimal use of bevacizumab in glioblastoma: a moving targetRoger Stupp, Michael Weller
Brain : a Journal of Neurology|November 25, 2015
New insights into acquired temozolomide resistance in glioblastoma?Caroline Happold, Michael Weller
Cancer|September 14, 2016
Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009Dorothee Gramatzki, Michael Weller
Pageof 94